This synergistic effect between Abi and Prog also suggests a potent therapeutic strategy for targeting MGMT-positive tumors, underscoring the potential of this combined treatment in overcoming TMZ resistance in GBM. The gene discussed is MGMT; the disease is glioblastoma.